Replies to post #65747 on Biotech Values

[rkrw]

If you think Doxapin from Somaxon is a doomed product because of generics, how about a low dose ambien for middle of the night dosing when you can split a generic? Why would managed care pay for this? Must be slim pickings out there for reverse mergers...

[DewDiligence]

NOVC closed off 24%. As noted in #msg-31869987, the announced reverse merger ascribes no value to NOVC’s pipeline because NOVC no longer has a pipeline. All it has is cash and a Nasdaq listing.

[DewDiligence]

RTRX proposes to acquire TSPT for $4/sh in cash:

http://finance.yahoo.com/news/retrophin-proposes-acquisition-transcept-4-200000456.html

The proposed buyout price is a 20% premium to yesterday’s closing price, but only an 11% premium to today’s.

Why is RTRX interested in TSPT? Presumably for the cash and NOL’s (see immediately following post).